Positive results from Phase IV study of MuGard (Access Pharma) for oral Mucositis

Results from the ongoing Phase IV clinical trial of mouth rinse treatment Mu-Gard, from Access Pharma, for oral Mucositis show that patients undergoing chemoradiation therapy for head and neck cancer and using Mu-Gard experienced a statistically significant reduction in mouth and throat soreness, a statistically significant delay to onset of oral Mucositis as measured in days or cumulative radiation, and statistically significant reductions in weight loss during therapy and in the use of opioid pain medication. Patients taking Mu-Gard throughout their treatment regimen had a statistically significant reduction in pain. They also experienced a statistically significant delay to onset of oral mucositis, which is important clinically and from a quality-of-life perspective. Finally Mu-Gard patients experienced a statistically significant reduction in weight loss between their start and completion of radiation treatment. The Mu-Gard benefits shown, to date, suggest broad application in patients at risk of this debilitating toxicity, according to Dr. Ron R. Allison, a principal investigator in the MuGard trial, Carolina Radiation Medicine, Greenville, NC. Results were presented at the Multinational Association of Supportive Care in Cancer Conference.